In addition, YTHDF2 also inhibits the expression of EPH receptor B3 (EPHB3) and Tumor Necrosis Factor α Induced Protein 3 (TNFAIP3) in an m6A-dependent manner, activating Phosphoinositide 3-Kinases (PI3K)/Akt and nuclear factor kappa-B (NF-κB) signaling, promoting resistance in GBM [164]. The gene discussed is EPHB3; the disease is glioblastoma.